Routine annual meeting filing with no immediate trading implications. Monitor future 10-Q filings for potential dilution from equity grants under the new plan.
Price Chart
Executive Summary
Protagonist Therapeutics held its 2026 Annual Meeting on June 17, 2026, where stockholders approved the new 2026 Equity Incentive Plan, replacing the 2016 plan and adding 650,000 new shares plus the prior plan's available reserve and returning shares. The election of two Class I directors and the ratification of Ernst & Young as auditor were also approved. This is a routine governance filing that does not change the company's operational outlook or financial position.
Key Facts
- Stockholders approved the 2026 Equity Incentive Plan, adding 650,000 new shares plus the prior plan's available reserve and returning shares to the share reserve.
- Two Class I directors were elected: Dinesh V. Patel, Ph.D. (48,714,702 for) and Lewis T. Rusty Williams, M.D., Ph.D. (45,371,193 for).
- Stockholder approval was received for executive compensation (say-on-pay) and the appointment of Ernst & Young as independent registered public accounting firm.
- The 2026 Plan replaces the 2016 Equity Incentive Plan and allows for grants of options, SARs, restricted stock, RSUs, and other stock-based awards.
- As of the record date (April 22, 2026), there were 64,305,185 shares of common stock outstanding and entitled to vote.
Financial Impact
Equity incentive plan refresh; 650,000 new shares authorized; no material near-term financial impact.
Risk Factors
- Potential dilution from future equity grants under the new plan.
- No change to operational or financial guidance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-075777 |
| Document: tm2618251d1_8k.htm | 0001104659-26-075777 |
| Document: 0001104659-26-075777-index-headers.html | 0001104659-26-075777 |
| Document: 0001104659-26-075777-index.html | 0001104659-26-075777 |
| Document: 0001104659-26-075777.txt | 0001104659-26-075777 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 144 | $148.29 $145.09 | ▲ +2.16% | ▲ +1.10% | $140.06 (+5.55%) |
Jun 18, 2026 15w ago | 8-K | $115.03 $140.91 | ▲ +22.50% | ▲ +22.65% | $140.06 (+21.76%) |
Jun 12, 2026 16w ago | Institutional Cluster | $109.78 $131.42 | ▲ +19.71% | ▲ +17.93% | $140.06 (+27.58%) |
May 12, 2026 20w ago | 144 | $103.88 $109.79 | ▼ −5.69% | ▼ −6.30% | $140.06 (−34.83%) |
May 8, 2026 21w ago | Insider Cluster | $99.36 $97.38 | ▼ −1.99% | ▼ −2.02% | $140.06 (+40.96%) |
May 8, 2026 21w ago | Insider Cluster | $99.36 $97.38 | ▼ −1.99% | ▼ −2.02% | $140.06 (+40.96%) |
May 5, 2026 21w ago | 8-K | $103.97 $95.41 | ▼ −8.23% | ▼ −11.01% | $140.06 (+34.71%) |
Feb 25, 2026 31w ago | 8-K | $87.10 $104.31 | ▲ +19.76% | ▲ +25.00% | $140.06 (+60.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access